Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Rhodiola rosea extract

Rhodiola rosea (salidroside / rosavins) · also known as Rhodiola, Salidroside, Rosavins, Salidroside

Rhodiola rosea extract is classed as an adaptogenic herb. A randomized trial in 60 people showed that a specific extract can lower the cortisol response after waking. It inhibits monoamine oxidase (MAO) in vitro, but there is not enough human evidence that usual oral doses inhibit MAO in the brain.

Typical dose: 200–500 mg/day, taken in the morning. Some products are standardized to 3% rosavins and 1% salidroside; specifications differ between products and are not directly interchangeable.
Absorption and forms: Some products are standardized to 3% rosavins and 1% salidroside, but this is only one product specification, not a ratio shared by every effective or authentic preparation. The claim that taking it on an empty stomach gives the best absorption is not backed by adequate comparison data. Avoid taking it in the evening, as it can be stimulating.

Clinical uses and human evidence

Fatigue and energy

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Olsson 2009 · Planta Med · RCT · n=60 — A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract shr-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue
  2. Ishaque 2012 · BMC Complement Altern Med · systematic review — Rhodiola rosea for physical and mental fatigue: a systematic review

Low mood

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Darbinyan 2007 · Nord J Psychiatry · RCT · n=89 — Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression
  2. Mao 2015 · Phytomedicine · RCT · n=57 — Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial

Endurance performance

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Wang 2025 · Front Nutr · meta-analysis · n=668 — The effect of Rhodiola rosea supplementation on endurance performance and related biomarkers: a systematic review and meta-analysis
  2. Sanz-Barrio 2023 · Phytother Res · systematic review · n=263 — Rhodiola rosea supplementation on sports performance: A systematic review of randomized controlled trials

Anxiety and stress

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Cropley 2015 · Phytother Res · RCT · n=80 — The Effects of Rhodiola rosea L. Extract on Anxiety, Stress, Cognition and Other Mood Symptoms

Mechanisms of action

Hypothalamic-pituitary-adrenal (HPA) axis blunting and cortisol stress buffering

★★★☆☆Mechanism evidence: grade ASecondary target

In a 60-person randomized controlled trial, 576 mg/day of a specific extract for 28 days produced a between-group difference in the salivary cortisol awakening response, measured directly in humans. This does not show that ACTH, receptor sensitivity or Hsp70 are also regulated. The trial dose was slightly higher than usual, and the result should not be generalized to all extracts.

References (1)
  1. Olsson 2009 · 60-person RCT: 576 mg/day of a specific extract for 28 days produced a between-group difference in the salivary cortisol response after waking

Monoamine neurotransmitter balance (dopamine, norepinephrine, 5-HT)

★☆☆☆☆Mechanism evidence: grade DSecondary target

Rhodiola extract and its components showed inhibitory activity in a recombinant human MAO system, an in-vitro result. Extract composition and pharmacokinetics vary considerably, and in-vitro inhibition does not show that effective concentrations are reached in the brain. There is also no reliable evidence that usual oral doses inhibit MAO in the human brain or change monoamine turnover.

References (2)
  1. van Diermen 2009 · Recombinant human MAO assay (in vitro): Rhodiola extract and components showed inhibitory activity
  2. Literature synthesis · Evidence gap: no reliable direct evidence that usual oral Rhodiola inhibits MAO in the human brain or changes monoamine turnover

Safety and drug interactions

Contraindicated in bipolar disorder, as it may trigger hypomanic episodes. People prone to insomnia should never take it late in the day or before bed. Safety and interactions with antidepressants and other psychoactive drugs are unclear and need to be checked by a doctor. Composition varies widely between products.

Serotonin excess risk

Has a weak MAO-inhibiting effect. Each of these raises serotonin levels in the brain. Taking two or more together carries a risk of serotonin syndrome, which causes agitation, sweating, a fast heartbeat, muscle twitching and fever. In severe cases it can be life-threatening.

With SSRIs, SNRIs and other serotonergic drugs Needs attention

Sertraline, fluoxetine, paroxetine, venlafaxine, duloxetine, tramadol, triptans (migraine drugs)

Has weak MAO-inhibiting activity; use together with caution.

With MAO inhibitors Needs attention

Phenelzine, selegiline, rasagiline, linezolid

Has weak MAO-inhibiting activity; use with caution alongside MAOIs.

Open in the interactive app ›